Managers / Q1 2020 · view latest →

KNOTT DAVID M

CIK 0000808722

Reported Value

$158M

Q1 2020

Positions

156

Filings on Record

2019–present window

Filed

May 13, 2020

original filing

Summary

Knott David M reported $158M in U.S.-listed holdings across 156 positions for Q1 2020.

Its largest position, LGND, represents 15.7% of the portfolio.

Compared with Q4 2019, the fund opened 18 new positions and exited 10.

Portfolio Metrics

Turnover

+10.2%

vs prior filed quarter

Top-10 Concentration

+59.7%

share of reported value

Largest Position

+15.7%

Ligand Pharmaceuticals Incorporated

New / Exited

18 / 10

positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value

Portfolio Composition

By security type

Common Stock · 80.9% · $128M
Other · 10.6% · $17M
PUBLIC · 5.3% · $8M
MLP · 2.7% · $4M
REIT · 0.5% · $796,000
Other · 0.1% · $109,000

Quarter-over-Quarter Changes full breakdown →

vs Q4 2019 (amended baseline)

Issuer	Move	Share Δ	Shares now	Value Δ	Value now
Fortress Trans & Infrastructure Inv. LLC	NEW	+888.5K	888.5K	+$7M	$7M
KKR KKR & Co. Inc.	NEW	+205.0K	205.0K	+$5M	$5M
ZGNXEUR Zogenix, Inc.	NEW	+52.8K	52.8K	+$1M	$1M
AKBA Akebia Therapeutics, Inc.	NEW	+135.2K	135.2K	+$1M	$1M
TREUR Trillium Therapeutics Inc.	NEW	+136.5K	136.5K	+$551,000	$551,000
ADMA ADMA Biologics, Inc.	NEW	+140.8K	140.8K	+$405,000	$405,000
RARXEUR RA Pharmaceuticals Inc.	NEW	+6.4K	6.4K	+$307,000	$307,000
ALIMEUR Alimera Sciences, Inc.	NEW	+75.2K	75.2K	+$301,000	$301,000

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2020

46 positions

Export to Excel

#	Issuer	Class	% Portfolio	Value ↓	Shares
1	LGND Ligand Pharmaceuticals Incorporated history →	Common	16.12%	$26M	351.2K
2	SRCLEUR Stericycle, Inc.history →	Common	8.25%	$13M	269.1K
3	APOEUR Apollo Global Management, Inc.history →	Common	7.88%	$12M	372.5K
4	UPLDEUR Upland Software, Inc.history →	Common	6.99%	$11M	413.0K
5	GOOG Alphabet Inc-Cl C history →	Common	5.80%	$9M	7.9K
6	Fortress Trans & Infrastructure Inv. LLC	Common	4.60%	$7M	888.5K
7	KKR KKR & Co. Inc.history →	Common	3.04%	$5M	205.0K
8	PFE Pfizer Inc.history →	Common	2.72%	$4M	131.9K
9	FSICUSD FS KKR Capital Corp.history →	Common	2.65%	$4M	1.40M
10	CCXIEUR ChemoCentryx, Inc.history →	Common	2.55%	$4M	100.4K
11	International Gaming Technologies	Common	2.25%	$4M	600.0K
12	LKQ1 LKQ Corporation history →	Common	1.94%	$3M	150.0K
13	BMY Bristol-Myers Squibb Company history →	Common	1.61%	$3M	45.9K
14	BLU BELLUS Health Inc.history →	Common	1.53%	$2M	242.6K
15	ABBV AbbVie Inc.history →	Common	1.45%	$2M	30.2K
16	Fannie Mae 8.25 percent Series T	Common	1.38%	$2M	396.7K
17	Calumet Specialty Products Partners, LP	Common	1.33%	$2M	2.00M
18	JPM JP Morgan Chase history →	Common	1.31%	$2M	23.1K
19	XENE Xenon Pharmaceuticals Inc.history →	Common	1.25%	$2M	175.2K
20	Fannie Mae Float Series P	Common	1.22%	$2M	336.4K
21	BioDelivery Sciences International, Inc.	Common	1.21%	$2M	505.5K
22	CLDNEUR Eiger BioPharmaceuticals, Inc.history →	Common	1.13%	$2M	263.7K
23	Horizon Therapeutics Public Ltd. Company	Common	1.11%	$2M	59.5K
24	KDMN Kadmon Holdings, Inc.history →	Common	1.01%	$2M	381.9K
25	ZGNXEUR Zogenix, Inc.	Common	0.82%	$1M	52.8K
26	MPLX MPLX LP	Common	0.73%	$1M	100.0K
27	CHRS Coherus Biosciences, Inc.	Common	0.69%	$1M	67.0K
28	AKBA Akebia Therapeutics, Inc.	Common	0.65%	$1M	135.2K
29	VKTX Viking Therapeutics, Inc.	Common	0.64%	$1M	218.1K
30	Cidara Therapeutics, Inc.	Common	0.63%	$997,000	402.1K
31	BAC Verizon Communications Inc.	Common	0.58%	$913,000	17.0K
32	AB AllianceBernstein Holdings PL Unit Ltd	Common	0.57%	$911,000	49.0K
33	Freddie Mac 8.375 percent Series Z	Common	0.54%	$850,000	139.5K
34	Alkermes PLC	Common	0.53%	$837,000	58.1K
35	COLL Collegium Pharmaceutical, Inc.	Common	0.51%	$801,000	49.1K
36	Global Medical REIT, Inc. Ser A Cum Pfd.	Common	0.51%	$801,000	35.0K
37	KMB Kimberly Clark Corporation	Common	0.48%	$767,000	6.0K
38	uniQure N.V.	Common	0.43%	$675,000	14.2K
39	JNJ Johnson & Johnson	Common	0.42%	$666,000	5.1K
40	MDLZ Mondelez Int'l Inc.	Common	0.41%	$651,000	13.0K
41	T AT&T Inc.	Common	0.37%	$583,000	20.0K
42	RDUSEUR Radius Health Inc.	Common	0.35%	$559,000	43.0K
43	TREUR Trillium Therapeutics Inc.	Common	0.35%	$551,000	136.5K
44	IBM International Business Machines	Common	0.30%	$475,000	4.3K
45	STMLEUR Stemline Therapeutics, Inc.	Common	0.27%	$435,000	89.9K
46	RHP Ryman Hospitality Ppty Inc.	Common	0.27%	$430,000	12.0K

Filing History

Quarter	Reported Value	Positions	Filed	Type	Links
Q3 2021	$275M	197	Nov 12, 2021	13F-HR	changes · EDGAR ↗
Q2 2021	$281M	195	Aug 13, 2021	13F-HR	changes · EDGAR ↗
Q1 2021	$234M	166	May 13, 2021	13F-HR	changes · EDGAR ↗
Q4 2020	$221M	145	Feb 12, 2021	13F-HR	changes · EDGAR ↗
Q3 2020	$170M	135	Nov 13, 2020	13F-HR	changes · EDGAR ↗
Q2 2020	$183M	127	Aug 12, 2020	13F-HR	changes · EDGAR ↗
Q1 2020	$158M	156	May 13, 2020	13F-HR	changes · EDGAR ↗
Q4 2019	$247M	152	Feb 14, 2020	13F-HR	changes · EDGAR ↗
Q3 2019	$238M	157	Nov 12, 2019	13F-HR	changes · EDGAR ↗
Q2 2019	$237M	148	Aug 12, 2019	13F-HR	changes · EDGAR ↗
Q1 2019	$251M	143	May 13, 2019	13F-HR	changes · EDGAR ↗
Q4 2018	$213M	133	Feb 12, 2019	13F-HR	changes · EDGAR ↗

Other Included Managers

This filing reports holdings on behalf of 1 additional manager.

DORSET MANAGEMENT CORP028-10281

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.